Physician profile
Deepali Tewari
NPI 1265728679
$26,863.79
in general payments reported to CMS, 2019-2025
14 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $40.30 · 2021: $97.05 · 2022: $67.60 · 2023: $16K · 2024: $10K · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $3,583 · Consulting Fee: $2,094 · Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,744.00 |
| Travel and Lodging | $3,583.14 |
| Consulting Fee | $2,094.00 |
| Food and Beverage | $1,873.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17,737.65 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $7,789.28 | 2023-2025 | Dupixent |
| Abbvie INC. | $247.64 | 2019-2021 | |
| Qol Medical, LLC | $247.26 | 2023-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $193.48 | 2023-2025 | Gattex, Eohilia |
| Boston Scientific Corporation | $157.78 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $141.21 | 2024 | Rexulti |
| Cumberland Pharmaceuticals, INC. | $94.29 | 2022-2023 | Kristalose |
| Nestle Healthcare Nutrition INC. | $72.17 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $57.29 | 2024 | |
| Janssen Biotech, INC. | $56.45 | 2019-2020 | |
| Alcresta Therapeutics, INC. | $25.67 | 2024 | Relizorb |
| Biocon Biologics INC | $24.61 | 2024 | Hulio |
| Travere Therapeutics, INC. | $19.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Tewari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.